Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06940180 · ClinicalTrials.gov registry record · Phase 2
Toripalimab With Chemotherapy for Sinus Cancer
A Phase 2 study of Squamous Cell Carcinoma and Sinonasal Undifferentiated Carcinoma, sponsored by Glenn J. Hanna.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06940180: Recruiting Phase 2 study of Squamous Cell Carcinoma and Sinonasal Undifferentiated Carcinoma, sponsored by Glenn J. Hanna.
NCT06940180 is a Phase 2 study of Squamous Cell Carcinoma and Sinonasal Undifferentiated Carcinoma that is actively recruiting participants, run by Glenn J. Hanna. The registered enrollment target is 20 participants, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06940180, a Phase 2 study of Squamous Cell Carcinoma and Sinonasal Undifferentiated Carcinoma, is actively recruiting participants, sponsored by Glenn J. Hanna.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers. The names of the study drugs used in this research study are: * Toripalimab (a type of monoclonal antibody) * Carboplatin (a type of antineoplastic agent) * Docetaxel (a type of antineoplastic agent) * Cisplatin (a type of antineoplastic agent)
Primary Outcome
pTRR is defined as the proportion of participants that experience a complete pathologic response or partial pathologic response during treatment, as defined in the RECIST criteria.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Cisplatin
- RADIATION Radiation Therapy
- DRUG Toripalimab
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
What NCT06940180 shows while recruiting
NCT06940180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (81% lower).
The record links to 5 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06940180 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06940180 about?
NCT06940180 is a clinical study titled "Toripalimab With Chemotherapy for Sinus Cancer". The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers. The names of the study drugs used in this ...
What is the current status of trial NCT06940180?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-06-17. Estimated completion is 2029-02-01.
What conditions does trial NCT06940180 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Sinonasal Undifferentiated Carcinoma, Paranasal Sinus Neoplasms, Locally Advanced Head and Neck Cancer, Sinonasal Cancer.
What interventions are being tested in trial NCT06940180?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Cisplatin (DRUG), Radiation Therapy (RADIATION), Toripalimab (DRUG).
Who is sponsoring clinical trial NCT06940180?
This trial is sponsored by Glenn J. Hanna, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06940180 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06940180's enrollment target sits among peer trials
20 40th of 47 higher than 6 of 47 other Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI